Results 121 to 130 of about 135,172 (298)

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study

Clinical Pharmacology &Therapeutics, EarlyView.
Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship remained to be determined ...
Samia Shabnaz, Eric Farber‐Eger, Marwa Tantawy, Neyousha Shahisavandi, Timothy J. Garrett, Samuel M. Rubinstein, Michael G. Fradley, Mohammed E. Alomar, Danny DeAvila, Kenneth H Shain, R. Frank Cornell, Daniel Lenihan, Qing Lu, Quinn S Wells, Rachid C. Baz, Yan Gong   +15 more
wiley   +1 more source

Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia

Clinical Pharmacology &Therapeutics, EarlyView.
Pediatric populations differ from adults in drug elimination capacity. While current scaling methods account for enzyme and transporter maturation, they overlook comorbidities, such as biliary atresia (BA), a liver disease appearing within the first 2–8 weeks of life that can progress to cirrhosis.
Zubida M. Al‐Majdoub, Martyn Howard, Brahim Achour, Jill Barber, Naved Alizai, Amin Rostami‐Hodjegan   +5 more
wiley   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

Clinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary, Robert Bies, Osei Boateng, Rachel Daley, Pierre Gashema, Mili Karina, Emily Njuguna, Sharon Nachman, Nathaniel Nkrumah, Carolyne Odula, Andrew Owen, Ethel D. Weld, Prajith Venkatasubramanian, Adeniyi Olagunju, on behalf of the Community of Practice for Long‐acting Therapeutics for Maternal and Paediatric Health, Rana Abutaima, Dorothy Akongo, Abdulnaser Alsharaa, Moherndran Archary, Shakir Atoyebi, Benoit Bestgen, Robert Bies, Osei Boateng, Andrew Butler, Edmund Capparelli, Rachel Daley, Layla Davies, Joelle Dountio, Henry Enzama, Pierre Gashema, Katila George, Dan Hawcutt, Rene Holm, Patrick Gad Iradukunda, Elodie Jambert, Mili Karina, Linda Lewis, Grace Miheso, Sebastien Morin, Andrew Morrison, Sharon Nachman, Shadia Nakalema, Emily Njunga, Nathaniel Nkrumah, Carolyne Odula‐Obonyo, Brenda Okware, Adeniyi Olagunju, Andrew Owen, Martina Penazzato, Natella Rakhmanina, Mphako Brighton Ratlabyana, Rachel Scott, Kimberly Struble, Andre‐Marie Tchouatieu, Catherine Unsworth, Prajith Venkatasubramanian, Catriona Waitt, Ethel Weld, Janine Winterbottom, Leena Zino   +59 more
wiley   +1 more source

Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC

Health Care Science, EarlyView.
Findings indicate that within a standardized clinical pathway integrating structured immunosuppression, therapeutic drug monitoring, and early complication surveillance, liver transplantation after ICI exposure can be performed safely without increased rejection risk.
Ning Wang, Zebin Zhu, Hao Zheng, Can Qi, Xiaodong Yuan, Xuefeng Li, Zhijun Xu, Jiwei Qin, Wei Wu, Jizhou Wang, Ruipeng Song, Zhiyong Guo, Lianxin Liu, Shu‐Geng Zhang, Björn Nashan   +14 more
wiley   +1 more source

HIV/AIDS Knowledge & Perceptions On a College Campus [PDF]

, 2018
Our research project surveyed students at Pace University (both on the New York City and Pleasantville campuses) and looked into their understanding of Human Immunodeficiency Virus (HIV) & Acquired Immunodeficiency Syndrome (AIDS). The goal was to better
Navarro, Gabriel
core   +1 more source

Pre-exposure Prophylaxis—Preventing HIV in Adolescents [PDF]

JAMA Pediatrics, 2021
Joseph Thomas, Whelihan, Maureen, Novak
openaire   +2 more sources

Unintended Consequences of Life‐Saving Pharmaceutical Innovations: How HAART Led to the Resurgence of Syphilis

Health Economics, EarlyView.
ABSTRACT Syphilis, a sexually transmitted infection that can lead to serious health complications, was almost eliminated in the United States by 2000. But since then, its incidence began to increase, recently reaching a 60‐year peak. We suggest that the introduction of the highly active antiretroviral therapy (HAART) drug regimen, which transformed HIV
David Beheshti, Scott Cunningham, Nir Eilam   +2 more
wiley   +1 more source

Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study. [PDF]

, 2017
Patients with prior invasive fungal infection (IFI) increasingly proceed to allogeneic hematopoietic cell transplantation (HSCT). However, little is known about the impact of prior IFI on survival.
Aljurf, M, Auletta, JJ, Battiwalla, M, Boeckh, MJ, Brazauskas, R, Chen, M, Dvorak, CC, Gea-Banacloche, J, Geroge, B, Guinan, EC, Hale, GA, Lazarus, HM, Lee, J-W, Liesveld, JL, Lindemans, CA, Martino, R, Maziarz, RT, McLeod, AA, Ramanathan, M, Reddy, V, Riches, ML, Savani, BN, Smith, FO, Strasfeld, L, Taplitz, RA, Ustun, C, Wingard, JR   +26 more
core  

Tolerability and efficacy of chemosaturation in combination with systemic therapy for metastatic uveal melanoma

International Journal of Cancer, EarlyView.
What's New? Uveal melanoma is the most common primary intraocular cancer in adults, and up to half of patients develop metastatic disease, predominantly in the liver, where prognosis remains poor despite promising treatment options. In this study, the authors evaluated the safety and efficacy of administering systemic therapy within 40 days of liver ...
Patrick Kasteleiner, Gerd Grözinger, Jörg Schmehl, Lukas Flatz, Andrea Forschner   +4 more
wiley   +1 more source

Cost‐effectiveness of a randomized controlled trial comparing low‐dose aspirin to placebo for the prevention of recurrent preterm birth

International Journal of Gynecology &Obstetrics, Volume 169, Issue 1, Page 399-407, April 2025.
Abstract To assess the cost‐effectiveness of low‐dose aspirin compared to placebo for the prevention of recurrent preterm birth from a healthcare perspective. This was a cost‐effectiveness analysis alongside a multicenter, randomized, double‐blinded, placebo‐controlled trial.
Anadeijda J. E. M. C. Landman, Hana M. Broulikova, Laura Visser, Tobias A. J. Nijman, Marieke A. C. Hemels, Karin C. Vollebregt, Elisabeth M. A. Boormans, Henk A. Bremer, Esther Tuinman, Josje Langenveld, Flip van der Made, Robbert J. P. Rijnders, Huib A. A. M. van Vliet, Liv M. Freeman, Roel de Heus, Judith Blaauw, Ineke Krabbendam, Rafli van de Laar, Marieke F. G. Verberg, Hubertina C. J. Scheepers, Ben W. Mol, Christianne J. M. de Groot, Martijn A. Oudijk, Judith E. Bosmans, Marjon A. de Boer   +24 more
wiley   +1 more source